Astegolimab

Summary

Astegolimab (CHEMBL4594385) is a phase-3 clinical-stage antibody; indicated across 4 conditions including chronic obstructive pulmonary disease and atopic eczema.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594385
Name	Astegolimab
Type	Antibody
Max phase	3

Also known as: AMG-282, AMG282, Astegolimab, MSTT-1041A, Mstt1041a, MSTT1041A, RG-6149, RG6149, RO-7187807, ASTEGOLIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
atopic eczema	2	MONDO:0004980	EFO:0000274
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
asthma	2	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05595642	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05878769	PHASE3	RECRUITING	A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02918019	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
NCT03615040	PHASE2	COMPLETED	Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
NCT03747575	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
NCT04386616	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
NCT05037929	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT06462118	PHASE1	COMPLETED	A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).